{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:05:07Z","timestamp":1781708707324,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,2]]},"DOI":"10.7759\/cureus.55374","type":"journal-article","created":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T12:11:06Z","timestamp":1709381466000},"source":"Crossref","is-referenced-by-count":2,"title":["Splenic Marginal Zone Lymphoma in a Patient With Antiphospholipid Syndrome Treated With Rituximab: A Case Report"],"prefix":"10.7759","author":[{"given":"Laxman","family":"Wagle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhiraj R","family":"Regmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samaj","family":"Adhikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parmartha","family":"Basnyat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Kalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjhh.2016.09.014","article-title":"Splenic marginal zone lymphoma: a literature review of diagnostic and therapeutic challenges","volume":"39","author":"Santos TS","year":"2017","unstructured":"Santos TS, Tavares RS, Farias DL. Splenic marginal zone lymphoma: a literature review of diagnostic and therapeutic challenges. Rev Bras Hematol Hemoter. 2017, 39:146-54. 10.1016\/j.bjhh.2016.09.014","journal-title":"Rev Bras Hematol Hemoter"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.743655","article-title":"Splenic marginal zone lymphoma: a population-based study on the 2001-2008 incidence and survival in the United States","volume":"54","author":"Liu L","year":"2013","unstructured":"Liu L, Wang H, Chen Y, Rustveld L, Liu G, Du XL. Splenic marginal zone lymphoma: a population-based study on the 2001-2008 incidence and survival in the United States. Leuk Lymphoma. 2013, 54:1380-6. 10.3109\/10428194.2012.743655","journal-title":"Leuk Lymphoma"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e328349ab8d","article-title":"Splenic marginal zone B-cell lymphoma: a distinct clinicopathological and molecular entity. Recent advances in ontogeny and classification","volume":"23","author":"Traverse-Glehen A","year":"2011","unstructured":"Traverse-Glehen A, Baseggio L, Salles G, Felman P, Berger F. Splenic marginal zone B-cell lymphoma: a distinct clinicopathological and molecular entity. Recent advances in ontogeny and classification. Curr Opin Oncol. 2011, 23:441-8. 10.1097\/CCO.0b013e328349ab8d","journal-title":"Curr Opin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/1076029620928392","article-title":"High incidence of antiphospholipid antibodies in newly diagnosed patients with lymphoma and a proposed aPL predictive score","volume":"26","author":"Kungwankiattichai S","year":"2020","unstructured":"Kungwankiattichai S, Nakkinkun Y, Owattanapanich W, Ruchutrakool T. High incidence of antiphospholipid antibodies in newly diagnosed patients with lymphoma and a proposed aPL predictive score. Clin Appl Thromb Hemost. 2020, 26:1076029620928392. 10.1177\/1076029620928392","journal-title":"Clin Appl Thromb Hemost"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.08.021","article-title":"Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma","volume":"134","author":"Gebhart J","year":"2014","unstructured":"Gebhart J, Lechner K, Skrabs C, et al.. Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma. Thromb Res. 2014, 134:980-4. 10.1016\/j.thromres.2014.08.021","journal-title":"Thromb Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199711)56:3%3C173::AID-AJH7%3E3.0.CO;2-V","article-title":"Immunological abnormalities in splenic marginal zone cell lymphoma","volume":"56","author":"Murakami H","year":"1997","unstructured":"Murakami H, Irisawa H, Saitoh T, et al.. Immunological abnormalities in splenic marginal zone cell lymphoma. Am J Hematol. 1997, 56:173-8. 10.1002\/(SICI)1096-8652(199711)56:3%3C173::AID-AJH7%3E3.0.CO;2-V","journal-title":"Am J Hematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2005.07.003","article-title":"Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients","volume":"35","author":"G\u00f3mez-Puerta JA","year":"2006","unstructured":"G\u00f3mez-Puerta JA, Cervera R, Espinosa G, et al.. Antiphospholipid antibodies associated with malignancies: clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum. 2006, 35:322-32. 10.1016\/j.semarthrit.2005.07.003","journal-title":"Semin Arthritis Rheum"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-2216","article-title":"Splenic marginal zone lymphoma","volume":"101","author":"Franco V","year":"2003","unstructured":"Franco V, Florena AM, Iannitto E. Splenic marginal zone lymphoma. Blood. 2003, 101:2464-72. 10.1182\/blood-2002-07-2216","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3816\/clm.2002.n.010","article-title":"Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients","volume":"3","author":"Thieblemont C","year":"2002","unstructured":"Thieblemont C, Felman P, Berger F, et al.. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymphoma. 2002, 3:41-7. 10.3816\/clm.2002.n.010","journal-title":"Clin Lymphoma"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2011.591381","article-title":"Autoimmune phenomena in untreated and treated marginal zone lymphoma","volume":"12","author":"Grabska J","year":"2011","unstructured":"Grabska J, Dasanu CA. Autoimmune phenomena in untreated and treated marginal zone lymphoma. Expert Opin Pharmacother. 2011, 12:2369-79. 10.1517\/14656566.2011.591381","journal-title":"Expert Opin Pharmacother"},{"key":"ref11","article-title":"APS syndrome in a patient with non-Hodgkin\u2019s lymphoma of the marginal zone: effectiveness of chemo-immunotherapy with fludarabina and rituximab","volume":"15","author":"Vacca A","year":"2000","unstructured":"Vacca A, Littera R, Carta M, Piras E, Oppi S, Arras M. APS syndrome in a patient with non-Hodgkin\u2019s lymphoma of the marginal zone: effectiveness of chemo-immunotherapy with fludarabina and rituximab. J Autoimmunol. 2000, 15:77.","journal-title":"J Autoimmunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.01.004","article-title":"Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab","volume":"47","author":"Bennett M","year":"2010","unstructured":"Bennett M, Schechter GP. Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab. Semin Hematol. 2010, 47:143-7. 10.1053\/j.seminhematol.2010.01.004","journal-title":"Semin Hematol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21931","article-title":"Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone","volume":"107","author":"Tsimberidou AM","year":"2006","unstructured":"Tsimberidou AM, Catovsky D, Schlette E, et al.. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer. 2006, 107:125-35. 10.1002\/cncr.21931","journal-title":"Cancer"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh308","article-title":"Normalization of anticardiolipin antibodies following rituximab therapy for marginal zone lymphoma in a patient with Sjogren's syndrome","volume":"43","author":"Harner KC","year":"2004","unstructured":"Harner KC, Jackson LW, Drabick JJ. Normalization of anticardiolipin antibodies following rituximab therapy for marginal zone lymphoma in a patient with Sjogren's syndrome. Rheumatology (Oxford). 2004, 43:1309-10. 10.1093\/rheumatology\/keh308","journal-title":"Rheumatology (Oxford)"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1177\/0961203307085251","article-title":"Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature","volume":"17","author":"Erre GL","year":"2008","unstructured":"Erre GL, Pardini S, Faedda R, Passiu G. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus. 2008, 17:50-5. 10.1177\/0961203307085251","journal-title":"Lupus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2018-224636","article-title":"Marginal zone lymphoma-associated antiphospholipid antibodies successfully treated with bendamustine rituximab","volume":"12","author":"Liu Z","year":"2019","unstructured":"Liu Z, Markham M, Mandernach MW. Marginal zone lymphoma-associated antiphospholipid antibodies successfully treated with bendamustine rituximab. BMJ Case Rep. 2019, 12:10.1136\/bcr-2018-224636","journal-title":"BMJ Case Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds643","article-title":"ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma","volume":"24","author":"Dreyling M","year":"2013","unstructured":"Dreyling M, Thieblemont C, Gallamini A, et al.. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol. 2013, 24:857-77. 10.1093\/annonc\/mds643","journal-title":"Ann Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2014.07.002","article-title":"Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation guidelines for the management of indolent, nonfollicular B-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphocytic lymphoma)","volume":"15","author":"Tarella C","year":"2015","unstructured":"Tarella C, Arcaini L, Baldini L, et al.. Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation guidelines for the management of indolent, nonfollicular B-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphocytic lymphoma). Clin Lymphoma Myeloma Leuk. 2015, 15:75-85. 10.1016\/j.clml.2014.07.002","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/232247-splenic-marginal-zone-lymphoma-in-a-patient-with-antiphospholipid-syndrome-treated-with-rituximab-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,2]],"date-time":"2024-03-02T12:11:08Z","timestamp":1709381468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/232247-splenic-marginal-zone-lymphoma-in-a-patient-with-antiphospholipid-syndrome-treated-with-rituximab-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,2]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.55374","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,2]]}}}